Download PDF
Semin Thromb Hemost 2012; 38(06): 613-621
DOI: 10.1055/s-0032-1321490
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Acquired Functional Coagulation Inhibitors: Review on Epidemiology, Results of a Wet-Workshop on Laboratory Detection, and Implications for Quality of Inhibitor Diagnosis

Myriam Dardikh
1   Department of Laboratory Medicine, Laboratory of Haematology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
,
Piet Meijer
2   ECAT Foundation, Leiden, The Netherlands
,
Felix van der Meer
3   Department of Thrombosis and Haemostasis, University Medical Centre Leiden, Leiden, The Netherlands
,
Emmanuel J. Favaloro
4   Department of Haematology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales, Australia
,
Bert Verbruggen
2   ECAT Foundation, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
27 June 2012 (online)

    Permissions and Reprints

Abstract

The accurate detection and quantification of coagulation inhibitors remains a challenging problem for most diagnostic laboratories. Prolonged screening assays and abnormal results of mixing tests with normal plasma may indicate the presence of such inhibitors. Yet, the presence of lupus anticoagulant, heparin, and potential contamination of plasma with therapeutically active antithrombotic drugs has to also be ruled out. This review covers the epidemiology of acquired functional coagulation inhibitors, and reports the results of a wet-workshop, organized by the External Quality Control for Assays and Test (ECAT) Foundation, on laboratory detection of such inhibitors. The aim of the workshop was to investigate, within groups of experts from dispersed professional laboratories, the quality of inhibitor detection and the difficulties encountered during the analytical process. In this workshop 8 samples representing varying milieu were tested by 10 groups of participants from 20 different countries. Workshop participants were asked to report the results of all investigations performed and to provide a likely diagnosis and/or a conclusion of the hemostasis abnormality represented by the test samples. Generally, the sensitivity of inhibitor detection was high but the differential diagnosis of the type of inhibitors identified was unsatisfactory, as many false-positive and false-negative results were observed. The most remarkable observation was the lack of a clear step-by-step analysis of the nature of an inhibitor once a positive mixing test had been detected. The possible consequences of these observations for the appropriate diagnosis and clinical management of patients are outlined. A diagnostic algorithm for the differential diagnosis and confirmation of acquired coagulation inhibitors is presented.

Keywords

coagulation inhibitors - diagnostic algorithm for inhibitor testing - antiphospholipid antibodies - lupus anticoagulants
 

  • References

  • 1 Coppola A, Favaloro EJ, Tufano A, Di Minno MND, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: part I - acquired hemophilia A. Semin Thromb Hemost 2012; 38 (5) 433-446
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Franchini M, Lippi G, Favaloro EJ. Acquired inhibitors of coagulation factors: part II. Semin Thromb Hemost 2012; 38 (5) 447-453
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Kershaw G, Favaloro EJ. Laboratory identification of factor inhibitors: an update. Pathology 2012; 44 (4) 447-453
    CrossrefPubMedGoogle Scholar
  • 4 Kershaw G, Suresh S, Orellana D, Nguy Y-M. Laboratory identification of lupus anticoagulants. Semin Thromb Hemost 2012; 38 (4) 375-384
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology 2011; 43 (7) 682-692
    CrossrefPubMedGoogle Scholar
  • 6 Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73 (2) 247-251
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Verbruggen B, Dardikh M, Polenewen R, van Duren C, Meijer P. The factor VIII inhibitor assays can be standardized: results of a workshop. J Thromb Haemost 2011; 9 (10) 2003-2008
    CrossrefPubMedGoogle Scholar
  • 8 Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation. Semin Thromb Hemost 2009; 35 (8) 786-793
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Dembitzer FR, Ledford Kraemer MR, Meijer P, Peerschke EI. Lupus anticoagulant testing: performance and practices by north American clinical laboratories. Am J Clin Pathol 2010; 134 (5) 764-773
    CrossrefPubMedGoogle Scholar
  • 10 Favaloro EJ, Bonar R, Duncan E , et al; RCPA QAP in Haematology Haemostasis Committee. Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. Thromb Haemost 2006; 96 (1) 73-78
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Favaloro EJ, Bonar R, Duncan E , et al. Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation. Pathology 2007; 39 (5) 504-511
    CrossrefPubMedGoogle Scholar
  • 12 Favaloro EJ, Bonar R, Kershaw G, Duncan E, Sioufi J, Marsden K. Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors. Semin Thromb Hemost 2009; 35 (8) 794-805
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Favaloro EJ, Bonar R, Kershaw G, Mohammed S, Duncan E, Marsden K. RCPA Haematology QAP Haemostasis Committee. Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia. Haemophilia 2010; 16 (4) 662-670
    PubMedGoogle Scholar
  • 14 Favaloro EJ, Wong RC. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. Clin Chem Lab Med 2011; 49 (3) 447-461
    CrossrefPubMedGoogle Scholar
  • 15 Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000; 15 (2) 145-151
    CrossrefPubMedGoogle Scholar
  • 16 Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346 (10) 752-763
    CrossrefPubMedGoogle Scholar
  • 17 Wilson WA, Gharavi AE, Piette JC. International classification criteria for antiphospholipid syndrome: synopsis of a post-conference workshop held at the Ninth International (Tours) aPL Symposium. Lupus 2001; 10 (7) 457-460
    CrossrefPubMedGoogle Scholar
  • 18 Miyakis S, Lockshin MD, Atsumi T , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (2) 295-306
    CrossrefPubMedGoogle Scholar
  • 19 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101 (5) 1827-1832
    CrossrefPubMedGoogle Scholar
  • 20 Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010; 376 (9751) 1498-1509
    CrossrefPubMedGoogle Scholar
  • 21 Urbanus RT, Derksen RH, de Groot PG. Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome. Blood Rev 2008; 22 (2) 93-105
    CrossrefPubMedGoogle Scholar
  • 22 Collins PW, Hirsch S, Baglin TP , et al; UK Haemophilia Centre Doctors' Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007; 109 (5) 1870-1877
    CrossrefPubMedGoogle Scholar
  • 23 Krishnamurthy P, Hawche C, Evans G, Winter M. A rare case of an acquired inhibitor to factor IX. Haemophilia 2011; 17 (4) 712-713
    CrossrefPubMedGoogle Scholar
  • 24 Bortoli R, Monticielo OA, Chakr RM , et al. Acquired factor XI inhibitor in systemic lupus erythematosus—case report and literature review. Semin Arthritis Rheum 2009; 39 (1) 61-65
    CrossrefPubMedGoogle Scholar
  • 25 Scott-Timperley LJ, Haire WD. Autoimmune coagulation disorders. Rheum Dis Clin North Am 1997; 23 (2) 411-423
    CrossrefPubMedGoogle Scholar
  • 26 Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia 2002; 8 (Suppl. 02) 23-29
    CrossrefPubMedGoogle Scholar
  • 27 Astermark J, Altisent C, Batorova A , et al; European Haemophilia Therapy Standardisation Board. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia 2010; 16 (5) 747-766
    CrossrefPubMedGoogle Scholar
  • 28 Brackmann HH, Gormsen J. Massive factor-VIII infusion in hemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 2: 933
    PubMedGoogle Scholar
  • 29 DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138 (3) 305-315
    CrossrefPubMedGoogle Scholar
  • 30 Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009; 15 (5) 1027-1031
    CrossrefPubMedGoogle Scholar
  • 31 Thorland EC, Drost JB, Lusher JM , et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 1999; 5 (2) 101-105
    CrossrefPubMedGoogle Scholar
  • 32 Warrier I. Factor IX antibody and immune tolerance. Vox Sang 1999; 77 (1, Suppl 1) 70-71
    CrossrefPubMedGoogle Scholar
  • 33 Lusher JM. Inhibitors in young boys with haemophilia. Best Pract Res Clin Haematol 2000; 13 (3) 457-468
    CrossrefPubMedGoogle Scholar
  • 34 Salomon O, Zivelin A, Livnat T , et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 2003; 101 (12) 4783-4788
    CrossrefPubMedGoogle Scholar
  • 35 Ang AL, Kuperan P, Ng CH, Ng HJ. Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost 2009; 101 (5) 852-859
    PubMedGoogle Scholar
  • 36 Streiff MB, Ness PM. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002; 42 (1) 18-26
    CrossrefPubMedGoogle Scholar
  • 37 Knöbl P, Lechner K. Acquired factor V inhibitors. Baillieres Clin Haematol 1998; 11 (2) 305-318
    CrossrefPubMedGoogle Scholar
  • 38 Savage WJ, Kickler TS, Takemoto CM. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure. Pediatr Blood Cancer 2007; 49 (7) 1025-1029
    CrossrefPubMedGoogle Scholar
  • 39 Favaloro EJ, Posen J, Ramakrishna R , et al. Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation. Blood Coagul Fibrinolysis 2004; 15 (8) 637-647
    CrossrefPubMedGoogle Scholar
  • 40 Bowman LJ, Anderson CD, Chapman WC. Topical recombinant human thrombin in surgical hemostasis. Semin Thromb Hemost 2010; 36 (5) 477-484
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Lippi G, Favaloro EJ, Montagnana M, Manzato F, Guidi GC, Franchini M. Inherited and acquired factor V deficiency. Blood Coagul Fibrinolysis 2011; 22 (3) 160-166
    CrossrefPubMedGoogle Scholar
  • 42 Dear A, Brennan SO, Sheat MJ, Faed JM, George PM. Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin lambda light chain. Haematologica 2007; 92 (11) e111-e117
    CrossrefPubMedGoogle Scholar
  • 43 Saif MW, Allegra CJ, Greenberg B. Bleeding diathesis in multiple myeloma. J Hematother Stem Cell Res 2001; 10 (5) 657-660
    CrossrefPubMedGoogle Scholar
  • 44 Llobet D, Borrell M, Vila L, Vallvé C, Felices R, Fontcuberta J. An acquired inhibitor that produced a delay of fibrinopeptide B release in an asymptomatic patient. Haematologica 2007; 92 (2) e17-e19
    CrossrefPubMedGoogle Scholar
  • 45 Gris JC, Schved JF, Branger B , et al. Autoantibody to plasma fibrinopeptide A in a patient with a severe acquired haemorrhagic syndrome. Blood Coagul Fibrinolysis 1992; 3 (5) 519-529
    CrossrefPubMedGoogle Scholar
  • 46 Ichinose A. Hemorrhagic acquired factor XIII (13) deficiency and acquired hemorrhaphilia 13 revisited. Semin Thromb Hemost 2011; 37 (4) 382-388
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Nijenhuis AV, van Bergeijk L, Huijgens PC, Zweegman S. Acquired factor XIII deficiency due to an inhibitor: a case report and review of the literature. Haematologica 2004; 89 (5) ECR14
    PubMedGoogle Scholar
  • 48 Gregory TF, Cooper B. Case report of an acquired factor XIII inhibitor: diagnosis and management. Proc (Bayl Univ Med Cent) 2006; 19 (3) 221-223
    PubMedGoogle Scholar
  • 49 Ajzner E, Muszbek L. Kinetic spectrophotometric factor XIII activity assays: the subtraction of plasma blank is not omissible [corrected]. [corrected] J Thromb Haemost 2004; 2 (11) 2075-2077
    CrossrefPubMedGoogle Scholar
  • 50 Mannucci PM, Tripoli A. Factor VIII clotting activity. In: Laboratory Techniques in Thrombosis. A Manual. 2nd revised edition. ECAT Assay Procedures. Dordrecht, The Netherlands: Kluwer Academic Publisher BV; 1999: 107-131
    CrossrefGoogle Scholar
  • 51 Clauss A. [Rapid physiological coagulation method in determination of fibrinogen]. Acta Haematol 1957; 17 (4) 237-246
    CrossrefPubMedGoogle Scholar
  • 52 Ortel TL. Laboratory diagnosis of the lupus anticoagulant. Curr Rheumatol Rep 2012; 14 (1) 64-70
    CrossrefPubMedGoogle Scholar
  • 53 Pengo V, Tripodi A, Reber G , et al; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7 (10) 1737-1740
    CrossrefPubMedGoogle Scholar
  • 54 Jennings I, Kitchen S, Kitchen DP, Woods TA, Walker ID. ISTH/SSC lupus anticoagulant testing guidelines: how far have these been adopted by laboratories?. J Thromb Haemost 2011; 9 (10) 2117-2119
    CrossrefPubMedGoogle Scholar
  • 55 Cunningham MT, Brandt JT, Laposata M, Olson JD. Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med 2002; 126 (4) 499-505
    PubMedGoogle Scholar
  • 56 Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995; 74 (6) 1597-1603
    PubMedGoogle Scholar
  • 57 Kitchen S, Jennings I, Preston FE, Kitchen DP, Woods TA, Walker ID. Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation. Semin Thromb Hemost 2009; 35 (8) 778-785
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S. International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17 (1) 2-10
    CrossrefPubMedGoogle Scholar
  • 59 Lippi G, Salvagno GL, Adcock DM, Gelati M, Guidi GC, Favaloro EJ. Right or wrong sample received for coagulation testing? Tentative algorithms for detection of an incorrect type of sample. Int J Lab Hematol 2010; 32 (1 Pt 2) 132-138
    CrossrefPubMedGoogle Scholar
  • 60 Ruinemans-Koerts J, Peterse-Stienissen I, Verbruggen B. Non-parallelism in the one-stage coagulation factor assay is a phenomenon of lupus anticoagulants and not of individual factor inhibitors. Thromb Haemost 2010; 104 (5) 1080-1082
    Article in Thieme ConnectPubMedGoogle Scholar